Barclays
DSGN icon

Barclays’s Design Therapeutics DSGN Stock Holding History

Barclays’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$148K Buy
11,771
+64
+0.5% +$884 ﹤0.01% 4142
2026
Q2 		$169K Sell
11,707
-44,083
-79% -$550K ﹤0.01% 3808
2026
Q1 		$594K Sell
55,790
-31,270
-36% -$316K ﹤0.01% 3082
2025
Q4 		$817K Sell
87,060
-1,116
-1% -$8.74K ﹤0.01% 3570
2025
Q3 		$664K Sell
88,176
-21,360
-20% -$107K ﹤0.01% 3625
2025
Q2 		$369K Buy
109,536
+25,530
+30% +$95.5K ﹤0.01% 3928
2025
Q1 		$324K Sell
84,006
-19,565
-19% -$93.4K ﹤0.01% 3784
2024
Q4 		$639K Buy
103,571
+6,936
+7% +$40.2K ﹤0.01% 3671
2024
Q3 		$520K Buy
96,635
+24,602
+34% +$116K ﹤0.01% 3752
2024
Q2 		$241K Sell
72,033
-16,875
-19% -$65.8K ﹤0.01% 3476
2024
Q1 		$358K Sell
88,908
-22,046
-20% -$58.9K ﹤0.01% 3791
2023
Q4 		$294K Buy
110,954
+39,276
+55% +$90K ﹤0.01% 4224
2023
Q3 		$169K Buy
71,678
+55,858
+353% +$261K ﹤0.01% 3376
2023
Q2 		$100K Sell
15,820
-1,397
-8% -$8.55K ﹤0.01% 3566
2023
Q1 		$99.3K Sell
17,217
-113,782
-87% -$851K ﹤0.01% 4184
2022
Q4 		$1.34M Buy
130,999
+109,401
+507% +$1.48M ﹤0.01% 2565
2022
Q3 		$361K Sell
21,598
-183,967
-89% -$3.66M ﹤0.01% 2872
2022
Q2 		$2.88M Sell
205,565
-20,946
-9% -$283K ﹤0.01% 1626
2022
Q1 		$3.66M Buy
+226,511
New +$3.47M ﹤0.01% 1421

Other funds holding DSGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Barclays's DSGN Position: Q3 2026 in Review

Barclays increased its Design Therapeutics (DSGN) stake by 0.55% in Q3 2026, buying an estimated $884 and bringing the position to 11,771 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #4142.

Barclays first reported a position in DSGN in Q1 2022 and has held it in 19 quarters since. The position peaked at $3.66M in Q1 2022. 85 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Barclays held 11,771 shares of Design Therapeutics worth $148K as of Q3 2026.
  • Barclays bought 64 Design Therapeutics shares in Q3 2026, an estimated $884.
  • Design Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4142 holding.
  • Barclays first reported a position in Design Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Design Therapeutics position peaked at $3.66M in Q1 2022.
  • 85 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.